Navigation Links
Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum
Date:9/5/2008

nd have the potential to form the basis for a new class of diagnostics and therapeutics. MicroRNAs have been shown to have different expression profiles in various pathological conditions. As a result, these differences may provide for a novel diagnostic strategy for many diseases.

About Rosetta Genomics

Rosetta Genomics (Nasdaq: ROSG) is a leader in the field of microRNA. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic and therapeutic tools, focusing primarily on cancer and various women's health indications. The first test based on the company's technology, differentiating squamous from non squamous non small cell lung cancer, is now approved through Columbia University Medical Center's High Complexity Molecular Pathology Laboratory. In Addition, the company expects two additional microRNA diagnostic tests applying its technology will be validated and submitted for regulatory approval by licensed clinical laboratories in the United States in 2008.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the potential of microRNAs extracted from blood to serve as effective biomarkers for a wide range of indications, including colon cancer, the role of microRNAs in human physiology and disease, the potential of microRNAs in
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. M. D. Anderson to Initiate Clinical Validation Study on Rosetta Genomics MicroRNA-based Diagnostic Assay Identifying the Origin of Cancer Metastases
2. First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology Receives Regulatory Approval
3. Rosetta Genomics and Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary and Metastatic Tumors in the Brain
4. Rosetta Genomics and Rabin Medical Center Announce a Collaboration Focused on MicroRNA-Based Diagnostics
5. Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer
6. Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
8. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
9. Orion Genomics Gains Exclusive Worldwide Rights to the IGF2 Gene for Colorectal Cancer Risk Testing Through Licensing Agreement With Johns Hopkins University
10. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
11. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 2014 Sanofi Pasteur, the vaccines division of Sanofi ... that the first lots of Fluzone ® (Influenza Vaccine) ... by the U.S. Food and Drug Administration (FDA) for distribution. ... first of at least 65 million doses of seasonal influenza ... U.S. health care providers and pharmacies in August. ...
(Date:7/22/2014)... AVIV, Israel , July 22, 2014 ... a clinical-stage biopharmaceutical company focused on the development and ... of liver diseases and cholesterol gallstones, announced today that ... cleared Galmed,s Investigational New Drug, or IND, application.  Such ... its product candidate, aramchol, in the United ...
(Date:7/22/2014)... , July 22, 2014  Neurotrope Bioscience, Inc., ... a world-wide, exclusive license agreement with the Icahn School ... ( Mount Sinai ) to utilize its ... Bryostatin-1 in the treatment of Niemann-Pick Type C Disease ... afflicted with Alzheimer-like symptoms. The license also covers other ...
Breaking Medicine Technology:Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 2Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 3Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 4Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 5Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 6Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 7Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 2Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 3Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 4Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 2Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 4Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 5
(Date:7/22/2014)... undergoing a minimally invasive hysterectomy using electric power morcellation, ... at the time of the procedure, according to a ... concern that this procedure, in which the uterus is ... of undetected malignancies. , Despite the commercial availability of ... the prevalence of malignancy at the time of electric ...
(Date:7/22/2014)... Marc, Ph.D., director of research at the University of ... by the International Society of Eye Research (ISER) as ... 2014 Paul Kayser International Award in Retina Research., The ... has made a significant contribution to the understanding of ... this week at the ISER Biennial Meeting in San ...
(Date:7/22/2014)... -- The American Society of Hematology (ASH) will present ... Award for Lifetime Achievement in Hematology, to Kanti R. ... (LIJ) School of Medicine for his 50-year career combining ... mentoring, and exceptional patient care. , The Wallace ... bestowed on an individual who has been a vital ...
(Date:7/22/2014)... As reported on July 17, 2014 by ... name her favorite beauty products, “ Botox , that’s pretty ... “ Botox has changed my life” by halving the ... for her various, daily appearances. “Suddenly my eyelids are ... goo.gl/shmTQM). , “I think that Kelly Ripa’s response to the ...
(Date:7/22/2014)... Autoimmune disorders may share certain pathogenic mechanisms with cancer, ... (GW) researcher Linda Kusner, Ph.D. , published in ... paradigm shifting work shows that the very same inhibitors ... expressed in cells that produce autoimmune diseases. Henry ... at the GW School of Medicine and Health Sciences ...
Breaking Medicine News(10 mins):Health News:Study examines presence of uterine cancers at the time of hysterectomy using morcellation 2Health News:University of Utah researcher Robert Marc receives Paul Kayser International Award 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 3Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 4Health News:Celebrity Botox: Kelly Ripa Confesses to Getting Botox Injections 2Health News:New research finds pathogenic connection between autoimmune disorders and cancer 2
... -- New research finds that compared to mammograms, MRI screenings ... the likelihood that high-risk, underserved women who were specially targeted ... big catch. Researchers were able to reduce the cost of ... the usual $3,500 -- thanks to a grant. As a ...
... Ohio People living in poor neighborhoods are at ... hospital than are people who live in wealthier neighborhoods, ... neighborhoods of differing socioeconomic status and out-of-hospital deaths caused ... 1992 and 2002. In each community, and among whites ...
... Industries LLC announced today the opening of a new expanded ... Ltd. The new facility will double the production capacity ... immune support ingredient. , "We are proud to announce the ... the increasing demand from around the world," said Ken-ichi Kosuna, ...
... the Mining Microbial Genomes for Novel Antibiotics research theme ... a recipient of the 2011 National Institutes of Health ... from some of the nation,s most promising new scientists. ... of five years, supports young investigators who have proposed ...
... Interventional Radiology Foundation,s Discovery Campaign, which seeks to further ... of discovery, announced a major corporate pledge to that ... St. Jude Medical, has pledged $100,000 and is a ... Medical Foundation strengthens SIR Foundation,s Discovery Campaign as it ...
... fertility-awareness based method of family planning developed by researchers ... Center so effectively meets the needs of users that they ... study finds that women who follow the Standard Days Method, ... it effectively. Results of the large, multi-country study of 1659 ...
Cached Medicine News:Health News:MRI Can Spot Breast Cancer in High-Risk Women: Study 2Health News:Living in poor neighborhood a risk factor for out-of-hospital cardiac death 2Health News:Living in poor neighborhood a risk factor for out-of-hospital cardiac death 3Health News:Society of Interventional Radiology Foundation accepts St. Jude Medical Foundation gift 2Health News:Long-term effectiveness of new family planning method shown in study 2
... The new Finnpipette Focus ... specifically to combine ergonomics with ... interchangeable handle plate offers a ... sizes. The new shorter tip ...
Inquire...
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
Medicine Products: